Sexual Health
KISSPEPTIN10 is a research-use product carried by vendors we track, grouped under Sexual Health. For research use only; an editorial review is pending.
KISSPEPTIN10 is offered by one or more vendors we track. We have not yet written a detailed editorial summary for this compound. The offerings below reflect what vendors currently carry. For research use only — verify dosing, handling, and safety against primary sources.
Where to buy
Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.
Evidence level
Preclinical only
A ten-amino-acid C-terminal fragment of the parent kisspeptin protein, retaining full biological activity at the KISS1R receptor. Studied for its role as a master regulator of the reproductive axis — triggering GnRH release upstream of LH/FSH. Used in research protocols for hypogonadism, ovulation induction, and exploration of reproductive endocrinology.
Mechanism
Mechanism not yet documented.
Researched benefits
Stimulation of the reproductive axis
Kisspeptin-10 acts on KISS1R receptors in the hypothalamus, triggering GnRH release and downstream LH and FSH secretion from the pituitary. In men, this produces an acute rise in testosterone within hours; in women, it can trigger ovulation under appropriate cycle conditions.
Diagnostic and ovulation-induction use
Kisspeptin-54 (the longer variant) has been studied in clinical trials as a safer alternative to hCG for triggering ovulation in IVF, with reduced risk of ovarian hyperstimulation syndrome (OHSS) — Jayasena et al. demonstrated successful oocyte maturation triggering with kisspeptin in a phase II trial.
Possible role in hypothalamic hypogonadism
Patients with congenital GnRH deficiency due to KISS1R loss-of-function mutations validate kisspeptin's central role. Exogenous kisspeptin can elicit GnRH/LH response in some forms of hypothalamic hypogonadism.
Investigational role in sexual response
Small human studies (Comninos et al.) have explored kisspeptin's effects on sexual and emotional brain processing using fMRI. Findings suggest enhanced limbic activity in response to sexual stimuli with kisspeptin infusion, but clinical implications remain exploratory.
Risks & cautions
Limited safety data outside research settings
Kisspeptin has been administered safely in clinical trial settings, but long-term out-of-clinic use is uncharacterized. The reproductive axis is a high-leverage target — sustained or supraphysiologic activation has theoretical risks.
Reproductive axis activation
By design, kisspeptin activates GnRH release. In women, this can disrupt cycle timing and trigger ovulation outside intended windows. In men with hypogonadism it is generally desirable but should be supervised.
OHSS risk in IVF settings
While kisspeptin's OHSS profile is more favorable than hCG, it is not zero. Ovulation triggering should occur in supervised reproductive medicine contexts.
Effects on hormone-sensitive conditions
Conditions modulated by sex steroids — endometriosis, fibroids, hormone-sensitive cancers, prostate disease — could be affected by induced HPG axis activation.
Dosing
Research protocols vary widely. Bolus IV doses of 0.3–3 nmol/kg have been used for acute GnRH/LH stimulation studies. Subcutaneous research protocols are not well standardized.
Vial sizes
--
Half-life
--
Route
--
Kisspeptin-10 has a short plasma half-life (~4 minutes), shorter than kisspeptin-54. Most published clinical research uses kisspeptin-54 for sustained reproductive axis effects; kisspeptin-10 is often the form sold in the research-peptide market. Dose-response and chronic dosing safety are not well characterized in non-research settings.
Contraindications
In depth
Kisspeptins are a family of peptides encoded by the KISS1 gene, originally identified as a metastasis-suppressor gene (hence the name — "Kiss" after Hershey kisses, where the gene was discovered at Penn State in Hershey, PA). Their reproductive role was uncovered in 2003 when two independent groups showed that loss-of-function mutations in KISS1R (also called GPR54) cause normosmic hypogonadotropic hypogonadism.
The full kisspeptin protein is processed into several active fragments: kisspeptin-54, -14, -13, and -10. All retain activity at KISS1R because the C-terminal 10 amino acids contain the receptor-binding region. Kisspeptin-10 is the most commonly sold research-peptide form, though kisspeptin-54 is more often used in published clinical research.
Kisspeptin acts on KISS1R (GPR54), a Gq-coupled receptor expressed on hypothalamic GnRH neurons. Activation produces:
Kisspeptin neurons in the arcuate nucleus (also called KNDy neurons — kisspeptin/neurokinin B/dynorphin) are the substrate for pulsatile GnRH release. Kisspeptin neurons in the AVPV (anteroventral periventricular) nucleus mediate the LH surge that triggers ovulation in females.
The KNDy network integrates inputs from sex steroid feedback, metabolic status (via leptin), and stress, which is why kisspeptin signaling explains the reproductive axis effects of nutritional deficit, obesity, and stress.
More robust than for many "research peptides":
Foundational and extensive. KISS1R knockout produces complete reproductive failure in mice. Kisspeptin administration restores function. The pharmacology is among the most thoroughly worked out in reproductive neuroendocrinology.
In a research-protocol context:
References
